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Abstract Bariatric surgery is recommended for Indian
patients with body mass index (BMI) >32.5 kg/m2 with at least
one comorbidity and >37.5 kg/m2 without a comorbidity. In
laparoscopic sleeve gastrectomy, bleeding and leakage from
the staple line are common post-operative events. Peri-Strips
Dry® with Veritas® (PSD-V) is used in staple-line reinforce-
ment. This was a single-investigator, multicenter, randomized
study of 100 patients undergoing standard sleeve gastrectomy
with a 34 or 36 French bougie. Patients were randomized 1:1
to PSD-Vor control groups; no buttress material was used in
the control group. The primary objective was to assess com-
plication rates (any staple-line bleed or leak from the intra-
operative visit through day 30) associated with sleeve gastrec-
tomy. Surgical time (from first incision to closure of last
incision) and the number of clips and/or sutures used to
control bleeding were also assessed. Fewer staple-line bleeds
were observed in the PSD-V group than the control group
(23/51 [45.1 %] vs 39/49 [79.6 %] patients; p=0.0005), and the
bleeding was of a lower severity (p=0.0002). No staple-line
leaks were observed. Surgical time was shorter in patients who
received PSD-V (58.8 vs 72.8 min; p=0.0153), and fewer
patients required hemostatic clips and/or sutures (10/51
[19.6%] vs 33/49 [67.3%] patients; p<0.0001). Fewer patients
in the PSD-V than the control group experienced adverse
events (2/51 [3.9 %] vs 5/49 [10.2 %] patients). The use of
PSD-V reduced the incidence and severity of staple-line
bleeding and was associated with a reduction in surgical time
compared with no staple-line reinforcement.
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Introduction
TheWorld Health Organization reports that >1.4 billion adults
are overweight and that nearly 500 million are obese,[1]
contributing to a global increase in obesity-related comorbid-
ities, including hypertension, type 2 diabetes mellitus, and
cardiovascular disease [2].
Obesity often occurs in developing countries in tandem
with under-nutrition, affecting nearly all ages and socioeco-
nomic groups [1]. In 2005–2006, 12.6 % of women and 9.7 %
of men were considered overweight or obese in India, based
on a body mass index (BMI) ≥25.0 [3]. However, it is now
recognized that Asian Indians are at greater risk of obesity-
related comorbidities at lower levels of BMI and waist
circumference/waist-to-hip ratio; therefore, alternative cutoff
points for definitions of “overweight” and “obese” may be
more appropriate [4, 5]. It is now recommended that an Indian
is considered overweight with a BMI of 23.0–24.9 kg/m2 and
obese with a BMI >25 kg/m2 [6].
The Consensus Statement for Asian Indians recommends
bariatric surgery for patients with a BMI >32.5 kg/m2 and a
comorbidity and for patients who have a BMI >37.5 kg/m2
without a comorbidity [6]. Sleeve gastrectomy evolved from a
larger gastric component of the duodenal switch with
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biliopancreatic diversion and is now widely accepted as a
primary bariatric operation [7]. The procedure has yielded
promising mid-term data, with reductions in BMI at 6 and
12 months post-surgery, in conjunction with cure of or im-
provement in major comorbidities [8].
Bleeding and leakage are common complications follow-
ing sleeve gastrectomy due to the long staple line. A
variety of intra-operative methods are used in preventing
these events, including over-sewing of staple lines and use
of linear staplers with shorter staple height. Staple-line
reinforcement is also beneficial, with reductions in opera-
tive time, limitation of post-operative gastric leakage and
bleeding, and fewer post-operative complications [9, 10],
though some surgeons also use sutures or clips for control
of hemorrhage.
A number of materials have been studied in staple-line
reinforcement, including porcine small intestinal submucosa
strips [11], absorbable polyglycolic acid [12], and bovine peri-
cardial strips [13, 14]. The use of integrated absorbable syn-
thetic polymers has proved feasible and is well tolerated [15],
and glycolide copolymer reinforcement sleeves have been
shown to reduce staple-line bleeding and may reduce gastroin-
testinal hemorrhaging [16]. Dapri et al. reported less blood loss
with the use of glycolide trimethylene carbonate copolymer
during stomach sectioning, although a recent study using the
same material showed no significant difference in bleeding and
post-operative leaks versus staple-line suturing [17, 18].
Peri-Strips Dry® with Veritas® (PSD-V; Synovis Life
Technologies, St. Paul, MN, USA) is an implantable biologic
tissue composed of non-cross-linked bovine pericardium,
treated with sodium hydroxide to reduce or inactivate trans-
missible spongiform encephalopathies/bovine spongiform en-
cephalopathies. The use of bovine pericardium strips has been
shown to reduce staple-line bleeding, with fewer days of
hospitalization compared with patients with no staple-line
reinforcement [14]. Recently, Hajj et al. 2013 reported that
bovine pericardium strips were associated with a lower staple-
line leak rate compared with over-sewing [19]. PSD-V, ap-
proved in the USA, has received the CE Mark (indicating
product compliance with European Union legislation) and has
recently been approved in India.
This clinical trial evaluated the benefits of using PSD-Vas
a staple-line reinforcement during sleeve gastrectomy surgery




This was a single-investigator, multicenter, randomized study
conducted at two sites (Ruby Hall Clinic and Poona Hospital
and Research Centre, Pune, India), with surgeries performed
between June 2011 and April 2012. The same surgical team
was present at both study sites.
Study methods were in compliance with the Indian Council
of Medical Research regulations (Ethical Guidelines for Bio-
medical Research on Human Participants) [20] and the Dec-
laration of Helsinki [21]. The study was approved by the
Ethics Committee of Poona Hospital and Research Centre
and by the Ethics Committee of Poona Medical Research
and Foundation. Study-specific informed consent forms were
provided for patients in three languages: English, Hindi, and
Marathi.
Patients
Inclusion and exclusion criteria for the study were in accor-
dance with guidelines for bariatric surgery [7]. Key inclusion
criteria included patient age between 18 and 75 years inclu-
sive, a BMI >32.5 kg/m2 with one or more comorbidities, or a
BMI >37.5 kg/m2 with no comorbidities. In addition, the
primary investigator had to consider the patient a good candi-
date for sleeve gastrectomy surgery. Exclusion criteria includ-
ed uncontrolled hypertension, current drug or alcohol abuse,
uncontrolled severe psychiatric illness, and disorders that may
contribute to obesity.
Procedures
Patients were randomized to PSD-Vor control groups in a 1:1
ratio, with randomization performed using sealed envelopes
that were opened immediately prior to surgery. The random-
ization block size was 6 and no randomization errors occurred.
Standard sleeve gastrectomy was performed using 34 or 36
French (Fr) bougies, consistent with guidelines reporting an
optimal bougie size of 32–36 Fr bougies [22]; the choice of a
34 or 36 Fr bougie was that of the operating surgeon and was
not pre-specified in the protocol. An Ethicon Echelon Linear
Surgical Stapler (Ethicon Endo-Surgery, Cincinnati, OH,
USA) was used in all cases, with 30 s of compression before
firing to exude fluid from the tissue and thereby ensure a more
uniform tissue thickness. In the group that received staple-line
reinforcement with PSD-V, only green staple cartridges
(2.0 mm) were used. In the control group, no buttress material
was used; the staples in the lower part of the stomach were
green (2.0 mm); and the staples in the upper part of the
stomach were blue (1.5 mm), consistent with findings that
tissue is thickest at the antrum and thinner toward the fundus
[23]. Green staples are more appropriate for thicker tissue, as
their wider diameter ensures they are stronger, and they form a
longer leg length [24]. In the absence of buttress material,
sutures or clips were used at the point of bleeding. Drains were
routinely placed in any patient considered to be at higher
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Table 1 Patient baseline
characteristics
aWilcoxon rank-sum test used to
compare continuous measures
between groups; Fisher’s exact
test used to compare categorical
measures between groups
BMI body mass index, IQR inter-
quartile range, PSD-V Peri-Strips
Dry® with Veritas®, SD standard
deviation
PSD-V, N=51 Control, N=49 p valuea
Age (years) Mean±SD 39.2±14.6 36.0±11.6 0.2087
Median (IQR) 38.2 (27.5, 50.0) 33.6 (26.9, 46.3)
Male gender % (n/N) 58.8 (30/51) 32.7 (16/49) 0.0099
Race
Asian Indian % (n/N) 98.0 (50/51) 100.0 (49/49) 1.0000
African % (n/N) 2.0 (1/51) 0.0 (0/49) 1.0000
Height (cm) Mean±SD 164.5±8.6 163.3±8.7 0.5047
Median (IQR) 163.0 (157.0, 172.4) 164.0 (157.0, 168.0)
Range 151.0–185.0 143.0–186.0
Weight (kg) Mean±SD 124.9±24.9 119.4±29.8 0.1699
Median (IQR) 122.8 (105.0, 144.0) 110.0 (100.8, 136.0)
Range 83.0–179.3 74.0–219.0
BMI Mean±SD 46.1±8.5 44.7±9.8 0.1967
Median (IQR) 43.6 (40.1, 51.1) 40.9 (38.0, 51.4)
Range 34.4–69.2 32.9–75.8
Table 2 Patient comorbidities
GERD gastroesophageal reflux
disease, PSD-V Peri-Strips Dry®
with Veritas®
a Fisher’s exact test used to com-
pare groups
PSD-V, N=51 Control, N=49 p valuea
Medical comorbidities, % (n/N)
Hypertension 29.4 (15/51) 36.7 (18/49) 0.5248
Hyperlipidemia 3.9 (2/51) 8.2 (4/49) 0.4316
Diabetes mellitus 23.5 (12/51) 20.4 (10/49) 0.8107
Sleep disorders 58.8 (30/51) 53.1 (26/49) 0.6873
GERD 0.0 (0/51) 2.0 (1/49) 0.4900
Depression 11.8 (6/51) 8.2 (4/49) 0.7412
Previous gastric surgery 0.0 (0/51) 2.0 (1/49) 0.4900
Other diseases and/or surgery, % (n/N)
Renal 0.0 (0/51) 4.1 (2/49) 0.2376
Gastrointestinal 2.0 (1/51) 4.1 (2/49) 0.6136
Respiratory 70.6 (36/51) 67.3 (33/49) 0.8296
Musculoskeletal 41.2 (21/51) 34.7 (17/49) 0.5417
Cardiovascular 11.8 (6/51) 24.5 (12/49) 0.1218
Other 94.1 (48/51) 95.9 (47/49) 1.0000
Table 3 Staple-line bleeds and leaks during sleeve gastrectomy surgery and in the subsequent 30 days for the full population
PSD-V Control
% (n/N) 95 % exact CI % (n/N) 95 % exact CI Difference (95 % exact CI) p valuea
Primary objective
Staple-line bleedsb 45.1 (23/51) 31.1, 59.7 79.6 (39/49) 65.7, 89.8 −34.5 % (−52.2, −15.7) 0.0005
Staple-line leaksc 0.0 (0/51) 0.0, 7.0 0.0 (0/49) 0.0, 7.3
CI confidence interval, PSD-V Peri-Strips Dry® with Veritas®
a Fisher’s exact test used to compare categorical measures between groups
b Patients with any reported bleed from the intra-operative visit through day 30
c Patients with any reported leak the intra-operative visit through day 30
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medical risk of complications, as a safety measure. Patients
underwent post-operative assessment on days 1, 7, and 30.
Objectives
The primary objective was to evaluate the complication rates
associated with sleeve gastrectomy, defined as any reported
staple-line bleed or leak from an intra-operative visit through
day 30. Intra-operative leaks were assessed using a methylene
blue and/or an air-leak test.
The following severity scale was used for the grading of
intra-operative staple-line bleeds:
& No bleed—the patient did not require a transfusion or
intervention for bleeding during the operation
& Mild bleed—a change in laboratory values that resolved
without further intervention
& Moderate bleed—a change in laboratory values with
bleeding that required clips, sutures, or stitches, or that
required a blood transfusion
& Severe bleed—the patient required an intervention, such
as a return to the operating room to correct a staple-line
bleed
The decision to transfuse was based on a combination of
clinical evaluation, changes in hemoglobin levels, and hemo-
dynamic monitoring. Bleeding severity was also assessed by
recording the number of bleeding points over the staple line;
in each case, the number of clips or sutures used to achieve
hemostasis for these bleeding points was recorded, as the
number of bleeding points was not necessarily the same as
the number of clips/sutures.
The secondary objective was to prospectively evaluate the
surgical time (from the first incision to the closure of the last
incision) and the number of clips and/or sutures used to
control bleeding in the PSD-V group versus the control group.
The time required for induction and reversal of anesthesia was
excluded to demonstrate real surgical time differences. Ad-
verse events (AEs) were assessed throughout the study period.
Data Analysis
The sample size was not statistically driven, as >1,000 patients
would be needed to reach statistical significance for post-
operative bleeds and gastric leaks. Data were summarized by
study arm using descriptive statistics (mean, standard devia-
tion [SD], median, interquartile range, range, counts, and
percentages), and 95 % confidence intervals were calculated
for the primary study objective. Fisher’s exact test was used to
compare categorical measures between the study arms, while
for continuous measures, comparisons were performed using
Wilcoxon rank-sum tests.
The severity of the patients’ worst bleed was compared
between groups using the Wilcoxon rank-sum test; patients
with no bleeds were given a score of 0, and patients with a
worst bleed severity of mild, moderate, or severe were
assigned scores of 1, 2, or 3, respectively. Nominal p values
were reported, and no adjustments for multiple comparisons
were made.
Results
Of the 100 patients who consented to study participation and
who were randomized to treatment, 46 were male and 54 were
Table 4 Staple-line bleeds and leaks during sleeve gastrectomy surgery and in the subsequent 30 days according to BMI
PSD-V, % (n/N) Control, % (n/N) Difference (95 % exact CI) p valuea Interaction p value
Staple-line bleeds based on BMIb
BMI <43 33.3 (7/21) 79.3 (23/29) −46.0 (−68.4, −18.3) 0.0015 0.4008
BMI ≥43 53.3 (16/30) 80.0 (16/20) −26.7 (−52.7, 2.4) 0.0742
BMI body mass index, CI confidence interval, PSD-V Peri-Strips Dry® with Veritas®
a Fisher’s exact test used to compare between groups
b Patients with any reported bleed from the intra-operative visit through day 30 (no leaks were reported)
Table 5 Severity of staple-line bleeds during sleeve gastrectomy and in
the subsequent 30 days
Severity of worst bleed % (n/N)
PSD-Va, N=51 Control, N=49
No bleed 54.9 (28/51) 20.4 (10/49)
Mild bleed 43.1 (22/51) 67.4 (33/49)
Moderate bleed 2.0 (1/51) 8.2 (4/49)
Severe bleed 0.0 (0/51) 4.1 (2/49)
PSD-V Peri-Strips Dry® with Veritas®
aWilcoxon rank-sum test used to assess the trend in severity of bleeds
between the groups (p=0.0002)
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female. All patients were followed to the end of the 30-day
study period. Patient baseline characteristics (Table 1) and
comorbidities (Table 2) were generally well balanced between
the treatment arms, but there were more males in the PSD-V
group than the control group (p=0.0099). PSD-V was used
along the length of the staple line in each sleeve gastrectomy;
the mean (±SD) number of PSD-V strips used in each case
was 6.9±1.2.
No intra-operative or post-operative leaks were reported in
either treatment arm. Fewer staple-line bleeds were observed
in the PSD-V group (23/51 [45.1 %] vs 39/49 [79.6 %]
patients), and this difference reached statistical significance
(p=0.0005; Table 3). Subgroup analyses in patients with a
BMI <43 also demonstrated fewer bleeds in the PSD-V group
compared with the control group (7/21 [33.3 %] vs 23/29
[79.3 %] patients; p=0.0015; Table 4). However, in patients
with a BMI ≥43, there was no significant difference between
the PSD-V and control groups (16/30 [53.3 %] vs 16/20
[80.0 %] patients; p=0.0742). BMI did not significantly in-
fluence the frequency of staple-line bleeds overall (interaction
p value for BMI, p=0.4008). Staple-line bleeding was of a
lower severity in the PSD-V group than the control (Table 5,
p=0.0002). Examination of post-operative bleed rates alone
showed no statistically significant difference between the
PSD-V and control groups (0/51 [0 %] vs 2/49 [4.1 %]
patients; p=0.2376).
In cases where the 36 Fr bougie was used, significantly
fewer patients in the PSD-V group experienced bleeds com-
pared with patients in the control group (13/28 [46.4 %] vs
31/34 [91.2 %] patients; p=0.0002). In contrast, in patients
treated with a 34 Fr bougie, there was no significant difference
between the treatment arms in the proportion of patients with
staple-line bleeds (PSD-V group, 10/23 [43.5 %] patients,
control group, 8/15 [53.3 %]; p=0.7409). A significant differ-
ence in treatment effect was observed across bougie sizes
(p=0.03).
The average surgical time was statistically significantly
shorter in the PSD-V group compared with the control group
(58.8 vs 72.8 min; p=0.0153 [Table 6]), and fewer patients
required hemostatic clips and/or surgical sutures (10/51
[19.6 %] vs 33/49 [67.3 %] patients, p<0.0001). Eight
patients required placement of multiple sutures along the
staple line (PSD-V group, n=2; control group, n=6). Two
patients in the control group were returned to the operating
room on post-operative day 1 due to bleeding.
There was no mortality in either treatment arm. In the PSD-V
group, two (3.9 %) patients experienced AEs (gastroenteritis,
n=1; intra-abdominal abscess [retrocecal psoas abscess],
n=1). Five (10.2 %) patients in the control group experienced
AEs: vomiting, n=2; gastroenteritis, n=1, and severe hemor-
rhage, n=2. Both patients with severe hemorrhage were
returned to the operating room on post-operative day 1 for
corrective surgery.
Discussion
In this single-center, randomized study, significantly fewer
staple-line bleeds were observed between the intra-operative
visit and day 30 with the use of PSD-V in comparison with the
control group receiving no staple-line reinforcement. The
staple-line bleeds in the PSD-V group were also of a lower
severity. These results are consistent with reports of a reduced
rate of staple-line failures with the use of bovine pericardium
as buttress material in sleeve gastrectomy [13, 19].
BMI did not significantly influence the frequency of staple-
line bleeds overall. However, subgroup analyses according to
BMI demonstrated fewer staple-line bleeds in patients with a
BMI ≤43 and in patients who received PSD-V compared with
the control group, but no difference was observed between
treatment groups in patients with a BMI >43. Tissue thickness
may be an important factor to consider in interpreting these
Table 6 Intra-operative data summary
PSD-V, N=51 Control, N=49 p valuea
Surgery time (min) Mean±SD 58.8±19.7 72.8±25.8 0.0153





Size of bougie 0.1538
34 Fr % (n/N) 45.1 (23/51) 30.6 (15/49) N/A
36 Fr % (n/N) 54.9 (28/51) 69.4 (34/49) N/A
Drain placed during surgery % (n/N) 88.2 (45/51) 91.8 (45/49) 0.7412
Fr French bougie, IQR interquartile range, NA not applicable, PSD-V Peri-Strips Dry® with Veritas®, SD standard deviation
aWilcoxon rank-sum test used to compare continuous measures between groups; Fisher’s exact test was used to compare categorical measures
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results, as a recent study examining the thickness of excised
sleeve gastrectomy specimens demonstrated that male gender
and BMI >50 kg/m2 were associated with thicker tissue in the
antrum [23]. This is of particular relevance to the present
study, as more males than females were recruited. To our
knowledge, the influence of BMI in studies of staple-line
reinforcement has not previously been examined; therefore,
further investigations are warranted to confirm the results of
the present study.
Bougie size was also found to significantly influence the
frequency of staple-line bleeds, with fewer bleeds overall in
the group that received the 34 Fr bougie compared with the 36
Fr bougie. However, the use of PSD-V was associated with a
lower bleed rate compared with the control group in patients
who received the 36 Fr bougie, whereas no difference was
observed between treatment groups in patients who received
the 34 Fr bougie. The reasons for this are unclear, and further
studies are needed to clarify these results.
No staple-line leaks were observed in either treatment
group, and therefore this study does not allow for inferences
regarding efficacy in gastric leaks. However, Stamou et al.,
2011 demonstrated no significant difference in staple-line leak
rates between patients who received PSD-V in sleeve gastrec-
tomy versus those who did not [14]. A review of the literature
by Chen et al. questioned the benefits of staple-line reinforce-
ment in reducing leaks, and this may be an area for clarifica-
tion in the future.[25]
Surgical time was significantly reduced in the PSD-V
group compared with the control group, with a difference of
14 min equating to almost 25% of the PSD-V procedure time.
The use of hemostatic clips and/or surgical sutures was also
significantly reduced with the use of PSD-V. A limitation of
the study is that the time for induction and reversal of anes-
thesia was excluded in order to demonstrate real surgical time
differences for sleeve gastrectomy, and this may be an area for
future investigation. Intra-operative time can be extended by
bleeding complications, and the need for suturing and clip-
ping. This is of considerable importance, as patients who
require sleeve gastrectomy frequently have comorbidities in
addition to morbid obesity, putting them at higher surgical
risk. Any factor that can reduce intraoperative bleeding re-
duces the time that high-risk patients are kept under anesthe-
sia, in turn reducing the risk of additional surgical
complications.
A further limitation to the present study is that it was
conducted at a single center, with a single surgical team, and
therefore the sample size is small. Further studies with larger
samples sizes would be beneficial to provide support for the
results.
There were no deaths during the study, and there was a low
incidence of AEs across the treatment groups. No safety issues
were raised with the use of PSD-V, in line with other studies
demonstrating that buttressing with bovine pericardium is
readily accomplished and well tolerated [19]. Stamou et al.
also reported that the use of PSD-V was associated with fewer
days of hospitalization for patients who had undergone sleeve
gastrectomy [14]. Thus, although the use of reinforcement
may incur additional costs, it is possible that this may be offset
by reductions in the number of days of hospitalization and is
an important consideration for future studies.
Conclusion
In conclusion, the use of PSD-V in patients with obesity alone,
and those who also had a history of hypertension, diabetes,
and/or sleep apnea, resulted in statistically significant de-
creases in the incidence and severity of intra-operative
staple-line bleeding and surgical time. Our results suggest that
PSD-V is a viable option for staple-line reinforcement in
patients undergoing sleeve gastrectomy.
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